{
    "clinical_study": {
        "@rank": "48395", 
        "arm_group": [
            {
                "arm_group_label": "Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Tablet 20 mg once daily for 30 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet once daily for 30 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to assess the effect of simvastatin on immunology, inflammatory, and\n      coagulation responses, and mortality in elderly with pneumonia based. The primary outcome is\n      mortality event.\n\n      The hypothesis of this study is that simvastatin therapy will reduce mortality in elderly\n      with pneumonia."
        }, 
        "brief_title": "Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Community-Acquired Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "Elderly patients diagnosed with pneumonia after getting information and signing informed\n      consent will be included in this trial. Simvastatin 20 mg will be administered to\n      intervention group, while control group will receive placebo. Both groups will receive drugs\n      (or placebo) for 30 days.\n\n      Baseline data will be collected within 24 hours after admission. Then the subject will be\n      followed up for 30 days. At the 7th day, patients will be underwent several laboratory\n      tests, i.e. serum TNF-\u03b1 (Tumor Necrosis Factor alpha), IFN-\u03d2 Interferon gamma), CRP\n      (C-Reactive Protein), and PAI-1 (Plasminogen Activator Inhibitor-1). Death from all causes\n      until 30 days will be recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Elderly patients with pneumonia\n\n        Exclusion Criteria:\n\n          -  Severe septic condition\n\n          -  Hepatic Cirrhosis\n\n          -  Acute coronary disease\n\n          -  Total cholesterol which is too high or too low\n\n          -  In anticoagulant therapy\n\n          -  In steroid therapy or other immunosuppressant therapy\n\n          -  Have refused to join the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651728", 
            "org_study_id": "48/PT02.FK/ETIK/2012", 
            "secondary_id": "U1111-1133-2403"
        }, 
        "intervention": [
            {
                "arm_group_label": "Simvastatin", 
                "description": "Tablet 20 mg once daily for 30 days", 
                "intervention_name": "Simvastatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CAS Number 79902-63-9", 
                    "ATC Code C10AA01"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "daily for 30 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Simvastatin", 
            "Pneumonia", 
            "Elderly", 
            "TNF-\u03b1", 
            "IFN-\u03d2", 
            "PAI-1", 
            "CRP"
        ], 
        "lastchanged_date": "August 2, 2012", 
        "location": {
            "contact": {
                "email": "kuntjoro.harimurti01@ui.ac.id", 
                "last_name": "Kuntjoro Harimurti, MD", 
                "phone": "+628159792380"
            }, 
            "facility": {
                "address": {
                    "city": "Jakarta Pusat", 
                    "country": "Indonesia", 
                    "state": "Jakarta", 
                    "zip": "10340"
                }, 
                "name": "Cipto Mangunkusumo Hospital"
            }, 
            "investigator": {
                "last_name": "Kuntjoro Harimurti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients: A Study of Immunological, Inflammatory, and Coagulation Responses in Relation to Reduce Mortality During Hospitalization", 
        "overall_contact": {
            "email": "kuntjoro.harimurti01@ui.ac.id", 
            "last_name": "Kuntjoro Harimurti, MD", 
            "phone": "+628159792380"
        }, 
        "overall_official": {
            "affiliation": "Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia", 
            "last_name": "Kuntjoro Harimurti, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Indonesia: Departement Kesehatan (Department of Health)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Death", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "reference": [
            {
                "PMID": "19531550", 
                "citation": "Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009 Jun 16;338:b2137. doi: 10.1136/bmj.b2137."
            }, 
            {
                "PMID": "18955636", 
                "citation": "Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, S\u00f8rensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008 Oct 27;168(19):2081-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651728"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Indonesia University", 
            "investigator_full_name": "Kuntjoro Harimurti", 
            "investigator_title": "M.D., M.Sc.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in TNF-\u03b1 (Tumor Necrosis Factor alpha) concentration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 7 days"
            }, 
            {
                "measure": "Change from baseline in Interferon-gamma (INF-\u03d2) concentration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 7 days"
            }, 
            {
                "measure": "Change from baseline in Plasminogen Activator Inhibitor-1 (PAI-1) concentration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 7 days"
            }, 
            {
                "measure": "Change from baseline in C-Reactive Protein (CRP) concentration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 7 days"
            }
        ], 
        "source": "Indonesia University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Indonesia University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}